Cigna (CI)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-07
$286.60+1.64%
Close 2026-07-07 · 1-day change
Reading CI? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CI free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-07
Reading CI? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CI free→QuarterlyIQ Insights · CI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-07-07.
The screen ranks CI against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Cigna aims to increase its adjusted income from operations, reaffirming a target of at least $30.35 per share for 2026.
Stated in 6 of last 6 quarters. EPS guidance increased from $29.60 in 2025 to $30.35 in 2026, indicating a focus on growth. The trajectory shows consistent reaffirmation of income targets, suggesting progress towards achieving the stated goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 50% of the time over the next year (vs 42% for the rest of the cohort, n=9129).
Over the trailing year it converted 1.40x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 49% of the time over the next year (vs 41% for the rest of the cohort, n=3127).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
19 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
Not investment advice. As of 2026-07-07.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Reaffirmed projected full year 2026 income of at least $30.35 per share.”
“Reaffirmed projected full year 2026 income of at least $30.25 per share.”
“Reaffirms 2025 outlook for adjusted income of at least $29.60 per share.”
“Reaffirms 2025 outlook for adjusted income of at least $29.60 per share.”
“Reaffirms 2025 outlook for adjusted income of at least $29.60 per share.”
“Reaffirms 2025 outlook for adjusted income of at least $29.60 per share.”
Cigna aims to achieve a pre-tax adjusted income from operations of at least $4.5 billion for Cigna Healthcare in 2026.
Cigna aims to achieve an adjusted revenue of approximately $280 billion for the full year 2026.